Treatment of Pain Associated With Fibromyalgia

NCT02146430 | Completed Phase 3 Results DMC

• 2 other identifiers: DS5565-A-E3092013-005161-40
• Study Type: interventional
• Target: 1,293
• Locations: 10 countries
• Sites: 161

Brief Summary

The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in subjects receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the participant that best describes his or her worst pain over the previous 24 hours.

Conditions

Pain Associated With Fibromyalgia

Keywords

pain; fibromyalgia

Outcome Measures

Primary Outcomes (1)

• Change From Baseline in Weekly Average Daily Pain Score (ADPS) at Week 13 in Participants Receiving DS-5565, Pregabalin, Placebo

  Average daily pain scores (ADPS) reported by the participant that best describes his or her worst pain over the previous 24 hours. A daily pain score has a scale where 0 = no pain to 10 = worst possible pain. Higher scores indicate a worse outcome. For participants with no Week 13 data, the baseline observation was carried forward (BOCF). The mean (multiple imputation estimate) and standard error (multiple imputation) are reported.

  Baseline up to Week 13 postdose

Secondary Outcomes (11)

• Number of Participants Who Answered "Much Improved or Better" in Patient Global Impression of Change (PGIC) at Week 13 in Participants Receiving DS-5565, Pregabalin, or Placebo

  Baseline up Week 13 postdose

• Change in Fibromyalgia Index Questionnaire (FIQ) Total Score From Baseline to Week 13 in Participants Receiving DS-5565, Pregabalin, or Placebo

  Baseline up to Week 13 postdose

• Number of Responders at Week 13 Among Participants Receiving DS-5565, Pregabalin, or Placebo

  Week 13 postdose

• Change From Baseline to Week 13 in Multidimensional Fatigue Inventory (MFI-20) General Fatigue Score in Participants Receiving DS-5565, Pregabalin, or Placebo

  Baseline up to Week 13 postdose

• Change From Baseline to Week 13 in Hospital Anxiety and Depression Scale (HADS) in Participants Receiving DS-5565, Pregabalin, or Placebo

  Baseline up to Week 13 postdose

Study Arms (4)

DS-5565 QD

EXPERIMENTAL

Participants take one each of placebo tablet and capsule in the morning, and one DS-5565 tablet once daily (QD) with a placebo capsule in the evening

Drug: DS-5565; Drug: Placebo tablet; Drug: Placebo capsule

DS-5565 BID

EXPERIMENTAL

Participants take one DS-5565 tablet and one placebo capsule, twice daily (BID)

Drug: DS-5565; Drug: Placebo capsule

Pregabalin

ACTIVE COMPARATOR

Participants take one pregabalin capsule and one placebo tablet BID

Drug: Pregabalin; Drug: Placebo tablet

Placebo

PLACEBO COMPARATOR

Participants take one each of placebo tablet and capsule BID

Drug: Placebo tablet; Drug: Placebo capsule

Interventions

DS-5565 DRUG

DS-5565 15 mg tablet for oral administration

Also known as: mirogabalin

DS-5565 BID; DS-5565 QD

Pregabalin DRUG

Pregabalin 150 mg capsule for oral administration

Also known as: Lyrica

Pregabalin

Placebo tablet DRUG

Placebo tablet (matching DS-5565) for oral administration

Also known as: Placebo matching DS-5565

DS-5565 QD; Placebo; Pregabalin

Placebo capsule DRUG

Placebo capsule (matching pregabalin) for oral administration

Also known as: Placebo matching pregabalin

DS-5565 BID; DS-5565 QD; Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years
• Able to give written informed consent
• Able to complete participant-reported questionnaires per the investigator's judgment
• At screening, participants must meet the 1990 American College of Rheumatology (ACR) criteria for fibromyalgia (FM), i.e. widespread pain present for at least 3 months and pain in at least 11 of 18 specific tender point sites. In addition, the 2010 ACR criteria must be met:
• Widespread pain index (WPI) ≥ 7 and symptom severity (SS) scale score ≥ 5, or WPI 3 to 6 and SS scale score ≥ 9
• Symptoms have been present at a similar level for at least 3 months
• The subject does not have a disorder that would otherwise explain the pain
• ADPS of ≥ 4 on the 11-point numeric rating scale (NRS) over the past 7 days prior to randomization (based on completion of at least 4 daily pain diaries during the 7-day baseline period prior to randomization)
• Subject must have documented evidence of a fundoscopic examination (with pupil dilation) within 12 months prior to screening or at screening.
• Women of child-bearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy during the study and for 4 weeks after study completion.

You may not qualify if:

• Clinically significant unstable neurologic, psychiatric, ophthalmologic, hepatobiliary, respiratory, or hematologic illness or unstable cardiovascular disease (e.g. severe hypotension, uncontrolled cardiac arrhythmia, or myocardial infarction) or any other concurrent disease within 12 months prior to screening that in the opinion of the investigator would interfere with study participation or assessment of safety and tolerability
• Anticipation of initiation or significant change to normal daily exercise routines or need for ongoing use of concomitant medications or non-pharmacological pain management techniques that may confound assessments of efficacy and/or safety
• Unable to undergo pre-study washout of prohibited concomitant medications
• Subjects who are at risk of suicide as defined by their responses to the Columbia-Suicide Severity Rating Scale (C-SSRS) or in the opinion of the investigator. Note: Patients answering "yes" to any of the questions about active suicidal ideation/intent/behaviors occurring within the past 12 months must be excluded (C-SSRS Suicide Ideation section - Questions 3, 4, or 5; C-SSRS Suicidal Behavior section, any of the suicide behaviors questions). Such patients should be referred immediately to a mental health professional for appropriate evaluation.
• Current severe or uncontrolled major depressive disorder or anxiety disorders as assessed by the Mini-international Neuropsychiatric Interview (MINI) mild to moderate major depression or anxiety disorders are permitted provided that the investigator assesses the patient as clinically stable and appropriate for entry into the study.
• Any diagnosis of lifetime bipolar disorder or psychotic disorder
• Participants with pain due to other conditions (e.g. diabetic peripheral neuropathic pain or post-herpetic neuralgia) that in the opinion of the investigator, would confound assessment or self-evaluation of the pain associated with FM.
• Participants with pain due to any widespread inflammatory musculoskeletal disorder (e.g. rheumatoid arthritis, lupus) or widespread rheumatic disease other than FM.
• Abuse or dependence of prescription medications, street drugs, or alcohol within the last 1 year
• Any history of a malignancy other than basal cell carcinoma within the past 5 years
• A diagnosis of untreated sleep apnea or initiation of treatment for sleep apnea within the past 3 months
• Pregnancy or breast-feeding, or intent to become pregnant during the study period
• Participant is currently enrolled in or has not yet completed at least 30 days since ending another investigational device or drug study or is receiving other investigational agents.
• Known hypersensitivity to alpha2-delta (α2δ) ligands or other components of the study medications. Note: Prior exposure to DS-5565 is allowed, as long as hypersensitivity to DS-5565 was not observed.
• Participants who are unlikely to comply with the protocol (e.g. uncooperative attitude, inability to return for subsequent visits) and/or otherwise considered by the investigator to be unlikely to complete the study.

Sponsors & Collaborators

• Daiichi Sankyo: lead
• Syneos Health: collaborator

Study Sites (165)

Unknown Facility

Glendale, Arizona, United States

Location

Unknown Facility

Phoenix, Arizona, United States

Location

Unknown Facility

Anaheim, California, United States

Location

Unknown Facility

Beverly Hills, California, 90211, United States

Location

Unknown Facility

Los Alamitos, California, 90720, United States

Location

Unknown Facility

Newport Beach, California, United States

Location

Unknown Facility

Oakland, California, United States

Location

Unknown Facility

Rancho Mirage, California, United States

Location

Unknown Facility

Roseville, California, 95661, United States

Location

Unknown Facility

San Diego, California, 92108, United States

Location

Unknown Facility

Sherman Oaks, California, 91403, United States

Location

Unknown Facility

Torrance, California, 90502, United States

Location

Unknown Facility

Tustin, California, 92780, United States

Location

Unknown Facility

Colorado Springs, Colorado, 80916, United States

Location

Unknown Facility

Denver, Colorado, 80209, United States

Location

Unknown Facility

Cromwell, Connecticut, United States

Location

Unknown Facility

Danbury, Connecticut, United States

Location

Unknown Facility

Boynton Beach, Florida, 33472, United States

Location

Unknown Facility

Bradenton, Florida, United States

Location

Unknown Facility

Brooksville, Florida, United States

Location

Unknown Facility

Coral Springs, Florida, United States

Location

Unknown Facility

Gainesville, Florida, United States

Location

Unknown Facility

Jacksonville, Florida, United States

Location

Unknown Facility

Lakeland, Florida, United States

Location

Unknown Facility

Miami, Florida, United States

Location

Unknown Facility

Ocala, Florida, United States

Location

Unknown Facility

Orlando, Florida, United States

Location

Unknown Facility

Port Orange, Florida, 32129, United States

Location

Unknown Facility

Royal Palm Beach, Florida, United States

Location

Unknown Facility

Sanford, Florida, United States

Location

Unknown Facility

St. Petersburg, Florida, 33707, United States

Location

Unknown Facility

Savannah, Georgia, 31406, United States

Location

Unknown Facility

Chicago, Illinois, 60634, United States

Location

Unknown Facility

Elwood, Indiana, 46036, United States

Location

Unknown Facility

Indianapolis, Indiana, United States

Location

Unknown Facility

Newton, Kansas, 67114, United States

Location

Unknown Facility

Wichita, Kansas, United States

Location

Unknown Facility

Wheaton, Maryland, 20902, United States

Location

Unknown Facility

Boston, Massachusetts, 02131, United States

Location

Unknown Facility

Fall River, Massachusetts, United States

Location

Unknown Facility

Methuen, Massachusetts, United States

Location

Unknown Facility

New Bedford, Massachusetts, United States

Location

Unknown Facility

Southfield, Michigan, 48034, United States

Location

Unknown Facility

Biloxi, Mississippi, 39531, United States

Location

Unknown Facility

Hattiesburg, Mississippi, United States

Location

Unknown Facility

Kansas City, Missouri, United States

Location

Unknown Facility

Springfield, Missouri, United States

Location

Unknown Facility

St Louis, Missouri, 63141, United States

Location

Unknown Facility

Omaha, Nebraska, 68114, United States

Location

Unknown Facility

Las Vegas, Nevada, 89102, United States

Location

Unknown Facility

Berlin, New Jersey, 08009, United States

Location

Unknown Facility

Princeton, New Jersey, United States

Location

Unknown Facility

Stratford, New Jersey, 08084, United States

Location

Unknown Facility

West Long Branch, New Jersey, United States

Location

Unknown Facility

Hartsdale, New York, 10530, United States

Location

Unknown Facility

New York, New York, 10168, United States

Location

Unknown Facility

Valley Stream, New York, United States

Location

Unknown Facility

Williamsville, New York, 14221, United States

Location

Unknown Facility

Charlotte, North Carolina, United States

Location

Unknown Facility

Durham, North Carolina, United States

Location

Unknown Facility

Greensboro, North Carolina, 27410, United States

Location

Unknown Facility

High Point, North Carolina, 27262, United States

Location

Unknown Facility

Raleigh, North Carolina, United States

Location

Unknown Facility

Winston-Salem, North Carolina, United States

Location

Unknown Facility

Cincinnati, Ohio, United States

Location

Unknown Facility

Middleburg Heights, Ohio, United States

Location

Unknown Facility

Toledo, Ohio, 43623, United States

Location

Unknown Facility

Oklahoma City, Oklahoma, United States

Location

Unknown Facility

Medford, Oregon, United States

Location

Unknown Facility

Allentown, Pennsylvania, 18104, United States

Location

Unknown Facility

Mechanicsburg, Pennsylvania, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19152, United States

Location

Unknown Facility

Anderson, South Carolina, United States

Location

Unknown Facility

Fountain Inn, South Carolina, United States

Location

Unknown Facility

Greenville, South Carolina, 29601, United States

Location

Unknown Facility

Summerville, South Carolina, 29485, United States

Location

Unknown Facility

Dakota Dunes, South Dakota, 57049, United States

Location

Unknown Facility

Tullahoma, Tennessee, United States

Location

Unknown Facility

Allen, Texas, 75013, United States

Location

Unknown Facility

Austin, Texas, 78731, United States

Location

Unknown Facility

Carrollton, Texas, 75007, United States

Location

Unknown Facility

Dallas, Texas, 75230, United States

Location

Unknown Facility

DeSoto, Texas, United States

Location

Unknown Facility

Houston, Texas, 77079, United States

Location

Unknown Facility

Lubbock, Texas, United States

Location

Unknown Facility

Mesquite, Texas, United States

Location

Unknown Facility

Plano, Texas, United States

Location

Unknown Facility

Richardson, Texas, 75080, United States

Location

Unknown Facility

Sugar Land, Texas, United States

Location

Unknown Facility

Bountiful, Utah, 84010, United States

Location

Unknown Facility

Seattle, Washington, United States

Location

Unknown Facility

Morgantown, West Virginia, United States

Location

Unknown Facility

Burlington, Canada

Location

Unknown Facility

Edmonton, Canada

Location

Unknown Facility

Kentville, Canada

Location

Unknown Facility

Kitchener, N2M 5N6, Canada

Location

Unknown Facility

London, N5W 6A2, Canada

Location

Unknown Facility

Markham, L3R 9W9, Canada

Location

Unknown Facility

Mississauga, L5B 4M4, Canada

Location

Unknown Facility

Newmarket, L3Y 5G8, Canada

Location

Unknown Facility

Oshawa, L1H 1G6, Canada

Location

Unknown Facility

Penticton, Canada

Location

Unknown Facility

Pointe-Claire, H9R 3J1, Canada

Location

Unknown Facility

Sarnia, N7T 4X3, Canada

Location

Unknown Facility

Sherbrooke, Canada

Location

Unknown Facility

Toronto, M3J 2C5, Canada

Location

Unknown Facility

Vancouver, Canada

Location

Unknown Facility

Winnipeg, Canada

Location

Unknown Facility

Choceň, Czechia

Location

Unknown Facility

Prague, Czechia

Location

Unknown Facility

Rychnov nad Kněžnou, Czechia

Location

Unknown Facility

Říčany, Czechia

Location

Unknown Facility

Aalborg, Denmark

Location

Unknown Facility

Odense, Denmark

Location

Unknown Facility

Hyvinkää, Finland

Location

Unknown Facility

Kokkola, Finland

Location

Unknown Facility

Amiens, France

Location

Unknown Facility

Cubray, France

Location

Unknown Facility

Élancourt, France

Location

Unknown Facility

Grenoble, France

Location

Unknown Facility

Paris, France

Location

Unknown Facility

Saint-Etienne, France

Location

Unknown Facility

Toulouse, France

Location

Unknown Facility

Bad Doberan, Germany

Location

Unknown Facility

Berlin, Germany

Location

Unknown Facility

Böhlen, Germany

Location

Unknown Facility

Chemnitz, Germany

Location

Unknown Facility

Cologne, Germany

Location

Unknown Facility

Cottbus, Germany

Location

Unknown Facility

Dresden, Germany

Location

Unknown Facility

Eichstätt, Germany

Location

Unknown Facility

Essen, Germany

Location

Unknown Facility

Fellbach, Germany

Location

Unknown Facility

Frankfurt, Germany

Location

Unknown Facility

Hamburg, Germany

Location

Unknown Facility

Jena, Germany

Location

Unknown Facility

Leipzig, Germany

Location

Unknown Facility

Mainz, Germany

Location

Unknown Facility

Marburg, Germany

Location

Unknown Facility

Mönchengladbach, Germany

Location

Unknown Facility

Munich, Germany

Location

Unknown Facility

Rodgau, Germany

Location

Unknown Facility

Stadtroda, Germany

Location

Unknown Facility

Wallerfing, Germany

Location

Unknown Facility

Weinheim, Germany

Location

Unknown Facility

Westerstede, Germany

Location

Unknown Facility

Wiesbaden, Germany

Location

Unknown Facility

Würzburg, Germany

Location

Unknown Facility

Beek, Netherlands

Location

Unknown Facility

Leiden, Netherlands

Location

Unknown Facility

Sneek, Netherlands

Location

Unknown Facility

Ålesund, Norway

Location

Unknown Facility

Hamar, Norway

Location

Unknown Facility

Hønefoss, Norway

Location

Unknown Facility

Kløfta, Norway

Location

Unknown Facility

Lier, Norway

Location

Unknown Facility

Lillehammer, Norway

Location

Unknown Facility

Stavanger, Norway

Location

Unknown Facility

Belgrade, Serbia

Location

Unknown Facility

Kragujevac, Serbia

Location

Unknown Facility

Niš, Serbia

Location

Unknown Facility

Novi Sad, Serbia

Location

Unknown Facility

Borås, Sweden

Location

Unknown Facility

Mölndal, Sweden

Location

Unknown Facility

Stockholm, Sweden

Location

Related Publications (1)

• Arnold LM, Whitaker S, Hsu C, Jacobs D, Merante D. Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study. Curr Med Res Opin. 2019 Oct;35(10):1825-1835. doi: 10.1080/03007995.2019.1629757. Epub 2019 Jul 9.

  PMID: 31284771 DERIVED

MeSH Terms

Conditions

Pain; Fibromyalgia

Interventions

mirogabalin; Pregabalin

Condition Hierarchy (Ancestors)

Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Muscular Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Neuromuscular Diseases; Nervous System Diseases

Intervention Hierarchy (Ancestors)

gamma-Aminobutyric Acid; Aminobutyrates; Butyrates; Acids, Acyclic; Carboxylic Acids; Organic Chemicals; Amino Acids; Amino Acids, Peptides, and Proteins

Results Point of Contact

• Title: Daiichi Sankyo US Contact for Clinical Trial Results
• Organization: Daiichi Sankyo, Inc.

CTRinfo@DSI.com

+1 (908) 992-6400

Study Officials

• Global Clinical Leader

  Daiichi Sankyo

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 21, 2014
• First Posted: May 23, 2014
• Study Start: October 27, 2014
• Primary Completion: July 14, 2016
• Study Completion: July 14, 2016
• Last Updated: November 9, 2020
• Results First Posted: November 9, 2020

Record last verified: 2020-11

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, CSR
• Time Frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
• Access Criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Locations

SE (3); FI (2); FR (7); CZ (4); CA (16); NO (7); US (92); NL (3); DK (2); DE (25)